Exploring mechanism of phenylethanoid glycosides against Alzheimer’s disease based on amyloid β⁃protein

CHEN Shengwei; XU Zheng; WANG Tianlin; CHEN Junjie

doi:10.16306/j.1008-861x.2023.01.009

您当前的位置：

首页 >

文章列表页 >

Exploring mechanism of phenylethanoid glycosides against Alzheimer’s disease based on amyloid β⁃protein

Experiment Research | 更新时间：2023-02-14

- Exploring mechanism of phenylethanoid glycosides against Alzheimer’s disease based on amyloid β⁃protein
- Academic Journal of Shanghai University of Traditional Chinese Medicine Vol. 37, Issue 1, Pages: 62-69(2023)
- 作者机构：
  
  1.南通市海门区人民医院（江苏　南通　226100）
  2.南京中医药大学（江苏　南京　210023）
  3.南通大学附属医院（江苏　　南通　226000）
- 作者简介：
- 基金信息：
- DOI：10.16306/j.1008-861x.2023.01.009
  CLC：
扫描看全文
陈胜玮,许峥,王天麟等.基于β淀粉样蛋白探讨苯乙醇苷类化合物抗阿尔茨海默症的作用机制[J].上海中医药大学学报,2023,37(01):62-69.

CHEN Shengwei,XU Zheng,WANG Tianlin,et al.Exploring mechanism of phenylethanoid glycosides against Alzheimer’s disease based on amyloid β⁃protein[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2023,37(01):62-69.
陈胜玮,许峥,王天麟等.基于β淀粉样蛋白探讨苯乙醇苷类化合物抗阿尔茨海默症的作用机制[J].上海中医药大学学报,2023,37(01):62-69. DOI： 10.16306/j.1008-861x.2023.01.009.

CHEN Shengwei,XU Zheng,WANG Tianlin,et al.Exploring mechanism of phenylethanoid glycosides against Alzheimer’s disease based on amyloid β⁃protein[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2023,37(01):62-69. DOI： 10.16306/j.1008-861x.2023.01.009.

摘要

目的,2,基于β淀粉样蛋白（Aβ）探讨苯乙醇苷类化合物抗阿尔茨海默症（AD）的作用机制。,方法,2,以天然产物库为筛选对象，运用软件Autodock以对接方法从库中筛选出与β分泌酶1（BACE1）对接较好的化合物，以对接打分作为挑选标准，挑选出候选化合物，并测试这些化合物在10 μmol/L时与BACE1的亲和力，分析候选化合物的结构特征，最终挑选1~2个化合物作为靶标分子，采用Western blot法检测与Aβ相关的蛋白表达水平。,结果,2,按照对接打分由高至低排序筛选出8个天然产物，其中3个化合物在10 μmol/L时与BACE1的结合力超过了60%；结构分析发现有2个化合物的结构均属于苯乙醇苷，最终挑选大车前苷和连翘酯苷作为靶标化合物；大车前苷和连翘酯苷对BACE1的IC,50,分别为（3.86±0.21）μmol/L和（4.52±0.29）μmol/L；大车前苷和连翘酯苷能显著下调大鼠神经元细胞中的BACE1、sAPPβ的表达水平（,P,<,0.05，,P,<,0.01，,P,<,0.001），上调α-分泌酶（ADAM10）的表达（,P,<,0.05，,P,<,0.01）。,结论,2,苯乙醇苷类化合物大车前苷和连翘酯苷能通过下调BACE1、sAPPβ，上调ADAM10的表达来抑制Aβ的表达，从而减缓AD的发展进程，这为基于Aβ通路抗AD的研究提供了优质的先导化合物。

Abstract

Objective,2,To explore the mechanism of phenylethanoid glycosides against Alzheimer’s disease （AD） based on amyloid β-protein （Aβ）.,Methods,2,Taking the natural product library as the screening object， the Autodock software was used to screen out compounds that were well docked with β-secretase 1 （BACE1） from the library by docking method. Grid Score was used as the selection standard to select candidate compounds. The affinity of these compounds with BACE1 at the concentration of 10 μmol/L was tested， and their structural characteristics were analyzed， and 1~2 compounds were finally selected as target molecules. Western blot was conducted to detect the expression levels of Aβ related proteins.,Results,2,Eight natural products were screened out according to Grid score from high to low. Among them， the binding affinity of 3 compounds with BACE1 was more than 60% at 10 μmol/L. The structural analysis showed that 2 compounds belonged to phenylethanoid glycoside. Plantamajoside and forsythiaside were finally selected as the target compounds. The IC50 of plantamajoside and forsythiaside against BACE1 were （3.86±0.21） μmol/L and （4.52±0.29） μmol/L， respectively. The expression levels of BACE1 and sAPPβ in rat neurons were significantly down-regulated by plantamajoside and forsythiaside（,P,<,0.05， ,P,<,0.01， ,P,<,0.001）， while the expression of α-secretase （ADAM10） was significantly up-regulated （,P,<,0.05， ,P,<,0.01）.,Conclusion,2,The phenylethanoid glycosides plantamajoside and forsythiaside can inhibit the expression of Aβ by down-regulating the expressions of BACE1 and sAPPβ and up-regulating the expression of ADAM10， which slows down the development of AD. And this provides the high quality of lead compounds for the research of Aβ pathway against AD.

关键词

阿尔茨海默症大车前苷连翘酯苷β淀粉样蛋白BACE1

Keywords

Alzheimer’s diseaseplantamajosideforsythiasideamyloid betaBACE1

references

温二生，薛进华，王凤珍，等. 姜黄素在AD治疗机制中的研究进展［J］. 赣南医学院学报， 2019， 39（5）： 525-527， 536.

WEN E S， XUE J H， WANG F Z， et. al. The progress of curcumin in the treatment mechanism of AD ［J］. Journal of Gannan Medical University， 2019， 39（5）： 525-527， 536.

BONDI M W， EDMONDS E C， SALMON D P. Alzheimer’s Disease：Past，Present，and Future［J］. J Int Neuropsychol Soc， 2017， 23（9-10）： 818-831.

LEE J M， DERKINDEREN P， KORDOWER J H， et al. The Search for a Peripheral Biopsy Indicator of α-Synuclein Pathology for Parkinson Disease［J］. J Neuropathol Exp Neurol，2017， 76（1）： 2-15.

CHANDLER L J， NEWSOM H， SUMNERS C， et. al. Chronic ethanol exposure potentiates NMDA excitotoxicity in cerebral cortical neurons ［J］. J Neurochem， 1993， 60（4）： 1578-1581.

CUCHILLO-IBAÑEZ I， LENNOL M P， ESCAMILLA S， et al. The apolipoprotein receptor LRP3 compromises APP levels［J］. Alzheimers Res Ther， 2021， 13（1）： 181.

NAKAMURA M， LI Y H， CHOI B R， et al. GDE2-RECK controls ADAM10 α-secretase-mediated cleavage of amyloid precursor protein［J］. Sci Transl Med， 2021， 13（585）： eabe6178.

GLENNER G G， WONG C W. Alzheimer’s disease： initial report of the purification and characterization of a novel cerebrovascular amyloid protein［J］. Biochem Biophys Res Commun， 1984， 120（3）： 885-890.

HARDY J， SELKOE D J. The amyloid hypothesis of Alzheimer’s disease： progress and problems on the road to therapeutics［J］. Science， 2002， 297（5580）： 353-356.

SCHELTENS P， DE STROOPER B， KIVIPELTO M， et al. Alzheimer’s disease［J］. Lancet， 2021， 397（10284）： 1577-1590.

LI Q Y， PENG J， LUO Y L， et al. Far infrared light irradiation enhances Aβ clearance via increased exocytotic microglial ATP and ameliorates cognitive deficit in Alzheimer’s disease-like mice［J］. J Neuroinflammation， 2022， 19（1）： 145.

MANTZAVINOS V， ALEXIOU A. Biomarkers for Alzheimer’s Disease Diagnosis［J］. Curr Alzheimer Res， 2017， 14（11）： 1149-1154.

FORTEA J， ZAMAN S H， HARTLEY S， et al. Alzheimer's disease associated with Down syndrome： a genetic form of dementia［J］. Lancet Neurol， 2021， 20（11）： 930-942.

冯治朋，高秀强，韩颜超，等. 连翘的研究进展［J］. 现代农业科技， 2018（12）： 60-62， 64.

FENG Z P， GAO X Q， HAN Y C， et. al. Research progress on Forsythia Suspensa（Thunb.）Vahl. ［J］. Modern Agricultural Science and Technology， 2018，（12）： 60-62， 64.

夏伟，董诚明，杨朝帆，等. 连翘化学成分及其药理学研究进展［J］. 中国现代中药， 2016， 18（12）： 1670-1674.

XIA W， DONG C M， YANG C F， et. al. Research progress on chemical constituents and pharmacology of Forsythia suspensa［J］. Modern Chinese Medicine， 2016， 18（12）： 1670-1674.

全云云，袁岸，龚小红，等. 连翘抗炎药效物质基础筛选研究［J］. 天然产物研究与开发， 2017， 29（3）： 435-438， 471.

QUAN Y Y， YUAN A， GONG X H， et. al. Investigation on anti-inflammatory components of Forsythia suspensa［J］.Natural Product Research and Development， 2017， 29（3）： 435-438， 471.

吴爱芝，林朝展，祝晨蔯. 苯乙醇苷类成分构效关系研究进展［J］. 天然产物研究与开发， 2013， 25（6）： 862-865.

WU A Z， LIN C Z， ZHU C C. Progress in structure-activity relationship of phenylethanoid glycosides［J］. Natural Product Research and Development， 2013， 25（6）： 862-865.

BEARA I N， LESJAK M M， JOVIN E D， et al. Plantain （Plantago L.） species as novel sources of flavonoid antioxidants［J］. J Agric Food Chem， 2009， 57（19）： 9268-9273.

胡嘉琪，李振宇. 中国植物志［M］. 第70卷. 北京：北京科学技术出版社， 2002.

HU J Q， LI Z Y. Flora Reipublicae Popularis Sinicae［M］. Vol.70. Beijing： Beijing Science and Technology Press， 2002.

王家葵，张瑞贤. 神农本草经［M］. 北京：北京：科学技术出版社， 2001.

WANG J K， ZHANG R X. Sheng Nong’s herbal classic［M］. Beijing： Beijing Science and Technology Press， 2001.

CHEN C， SHANG C， XIN L Y， et al. Beneficial effects of psyllium on the prevention and treatment of cardiometabolic diseases［J］. Food Funct， 2022， 13（14）： 7473-7486.

JI X L， HOU C Y， GUO X D. Physicochemical properties， structures， bioactivities and future prospective for polysaccharides from Plantago L. （Plantaginaceae）： A review［J］. Int J Biol Macromol， 2019， 135： 637-646.

YAMADA H， NAGAI T， TAKEMOTO N， et al. Plantagoside， a novel α-mannosidase inhibitor isolated from the seeds of Plantago asiatica， suppresses immune response［J］. Biochem Biophys Res Commun， 1989， 165（3）： 1292-1298.

SATHYA M， PREMKUMAR P， KARTHICK C， et al. BACE1 in Alzheimer’s disease［J］. Clin Chim Acta， 2012， 414： 171-178.

DAS B， YAN R Q. Role of BACE1 in Alzheimer’s synaptic function［J］. Transl Neurodegener， 2017， 6： 23.

HAMPEL H， VASSAR R， DE STROOPER B， et al. The β-Secretase BACE1 in Alzheimer’s Disease［J］. Biol Psychiatry， 2021， 89（8）： 745-756.

WÓJTOWICZ S， STROSZNAJDER A K， JEŻYNA M， et al. The Novel Role of PPAR Alpha in the Brain： Promising Target in Therapy of Alzheimer’s Disease and Other Neurodegenerative Disorders［J］. Neurochem Res， 2020， 45（5）： 972-988.

AHMAD S S， KHAN S， KAMAL M A， et al. The Structure and Function of α， β and γ-Secretase as Therapeutic Target Enzymes in the Development of Alzheimer’s Disease： A Review［J］. CNS Neurol Disord Drug Targets， 2019， 18（9）： 657-667.

KIM N， LEE H J. Redox-Active Metal Ions and Amyloid-Degrading Enzymes in Alzheimer’s Disease［J］. Int J Mol Sci， 2021， 22（14）： 7697.

PERON R， VATANABE I P， MANZINE P R， et al. Alpha-Secretase ADAM10 Regulation： Insights into Alzheimer’s Disease Treatment［J］. Pharmaceuticals （Basel）， 2018， 11（1）： 12.

ALEXOPOULOS P， THIERJUNG N， GRIMMER T， et al. The Alzheimer’s Disease Neuroimaging Initiative. Cerebrospinal Fluid BACE1 Activity and sAβPPβ as Biomarker Candidates of Alzheimer’s Disease［J］. Dement Geriatr Cogn Disord， 2018， 45（3-4）： 152-161.

RESENDE R， FERREIRA-MARQUES M， MOREIRA P， et al. New BACE1 Chimeric Peptide Inhibitors Selectively Prevent AβPP-β Cleavage Decreasing Amyloid-β Production and Accumulation in Alzheimer’s Disease Models［J］. J Alzheimers Dis， 2020， 76（4）： 1317-1337.

WU M， DOROSH L， SCHMITT-ULMS G， et al. Aggregation of Aβ40/42 chains in the presence of cyclic neuropeptides investigated by molecular dynamics simulations［J］. PLoS Comput Biol， 2021， 17（3）： e1008771.

Views

277

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

⁰